Clinical Research Directory
Browse clinical research sites, groups, and studies.
Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease
Sponsor: Daihong Liu
Summary
This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.
Official title: An Exploratory Clinical Study of Low-Dose Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease
Key Details
Gender
All
Age Range
Any - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-01-17
Completion Date
2027-12-30
Last Updated
2026-05-08
Healthy Volunteers
No
Conditions
Interventions
steroids 、ruxolitinib
Patients with acute grade II GVHD are treated with a combination of methylprednisolone (0.5 mg/kg/day) and ruxolitinib.
Locations (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, China